In:
British Journal of Clinical Pharmacology, Wiley, Vol. 89, No. 3 ( 2023-03), p. 1216-1221
Abstract:
Rifampicin, a potent enzyme inducer, causes marked reduction of dolutegravir exposure. Rifabutin, a less potent enzyme inducer, may offer an alternative to rifampicin. We aimed to characterize the population pharmacokinetics of dolutegravir when co‐administered with rifabutin. We extended an existing dolutegravir model to include data from volunteers co‐administered with dolutegravir 50 mg and rifabutin 300 mg once daily. We ran simulations of dolutegravir with and without rifabutin co‐administration and compare dolutegravir trough concentrations with the IC 90 and EC 90 of 0.064 and 0.3 mg/L, respectively. Rifabutin decreased dolutegravir's volume of distribution by 33.1% (95% confidence interval 25.1%–42.3%) but did not affect the area under the concentration–time curve. Simulations showed that when 50 mg dolutegravir is co‐administered with rifabutin once daily, the probability to attain trough concentrations above the IC 90 of 0.064 mg/L is more than 99%. Therefore, there is no need for dolutegravir dose adjustment. Rifabutin may offer an alternative to rifampicin for the treatment of HIV/tuberculosis co‐infected individuals.
Type of Medium:
Online Resource
ISSN:
0306-5251
,
1365-2125
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
1498142-7
SSG:
15,3
